Kimball Electronics, Inc. — Form 10-Q Summary
Business context and period: Global manufacturing-solutions provider serving automotive, medical, and industrial markets. This unaudited filing covers the first quarter of fiscal 2024, the three months ended September 30, 2023, compared with the three months ended September 30, 2022, except balance-sheet comparisons, which are to June 30, 2023.
Financial results
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Net sales | $438.1 million | $405.9 million | +8% |
| Gross profit / margin | $35.5 million / 8.1% | $29.3 million / 7.2% | Margin +0.9 percentage points |
| Operating income / margin | $19.5 million / 4.4% | $13.6 million / 3.3% | Income +44% |
| Net income | $10.8 million | $9.5 million | +13% |
| Diluted EPS | $0.43 | $0.38 | +13% |
| Operating cash flow | $12.8 million | $(60.2) million | Improved |
| Capital expenditures | $11.2 million | $19.3 million | Lower |
Revenue by end market: automotive $212.5 million (+13%), medical $102.4 million (−12%), and industrial $123.2 million (+21%). Foreign currency movements contributed a favorable 1% to sales growth. The company recast prior-period vertical-market sales presentation to conform to its current presentation.
Cash from operations reflected net income and noncash items of $22.5 million, partly offset by $9.7 million used by operating asset and liability changes. Inventory growth used $34.0 million of cash; lower receivables provided $45.3 million. Cash and cash equivalents were $56.6 million at quarter-end; including restricted cash, cash-flow statement cash totaled $58.8 million.
Balance sheet, debt, and liquidity
- Total borrowings under credit facilities were $296.7 million, versus $281.5 million at June 30, 2023; the weighted-average borrowing rate rose to 7.1% from 6.8%. Current maturities were $61.7 million and long-term debt was $235.0 million.
- Working capital was $452.7 million; current ratio was 1.9, compared with 2.0 at fiscal year-end. Debt-to-equity was 0.6, versus 0.5.
- Management reported $147.1 million of short-term liquidity, defined as cash and cash equivalents plus unused credit facilities, some of which are uncommitted. Unused facility capacity was $90.5 million.
- The company reported compliance with credit-facility financial covenants. Its $50 million secondary revolving facility matures February 2, 2024; management said it would evaluate renewal as maturity approaches. The primary facility matures May 4, 2027.
- Cash conversion days increased to 103 from 94 a year earlier, mainly reflecting higher production inventory days. Management expects inventory and working capital to normalize as component shortages ease and expanded capacity ramps up.
Material changes and management commentary
- Automotive growth reflected program ramp-ups, new launches, and improved component availability; industrial growth was driven largely by program ramp-ups.
- Medical sales declined primarily because a large customer was remediating a recall. The company stated the recall was unrelated to products it supplied.
- Gross margin improved as the company continued to optimize operating performance following facility expansions. Selling and administrative expense remained nearly flat in dollars and declined as a percentage of sales.
- Interest expense increased to $5.4 million from $1.9 million, attributed to higher interest rates and greater borrowings. Other expense was $6.3 million, versus $1.4 million a year earlier.
- Open orders were $907 million, down 15% year over year, primarily due to reduced orders from the medical customer addressing the recall. Orders may be delayed or canceled, and the filing cautions that open orders may not predict future sales.
- The company sold $103.0 million of receivables without recourse during the quarter, compared with $97.6 million in the prior-year quarter. It reported no material off-balance-sheet arrangements.
Outlook, risks, and contingencies
No specific quarterly or annual earnings or revenue guidance is provided. Management believes cash on hand, operating cash generation, and borrowing availability will be sufficient for working-capital and other operating needs for at least the next 12 months. Capital expenditure commitments were approximately $12 million. Management also noted plans for continued prudent investment, including capacity expansions and potential acquisitions.
Risks highlighted include component shortages, allocations and shipping delays; inflation in components, labor, freight, and other costs; customer demand fluctuations; competitive pricing and margin pressure; foreign-exchange movements; geopolitical and broader economic uncertainty; and dependence on replacing expiring customer programs. Management said shortages and extended inventory lead times have affected working capital and profitability, and the future financial impact cannot be reasonably estimated but could be material. The secondary credit facility’s 2024 maturity is also a near-term liquidity item to monitor.
Routine litigation and claims were not expected to have a material adverse effect. Product warranty expense and liability were immaterial. The board-authorized repurchase plan had $11.2 million remaining; no shares were repurchased in the quarter. Disclosure controls were assessed as effective, with no material changes to internal control over financial reporting reported.
Important facts for investors to verify
- Whether automotive and industrial program ramps offset continuing medical-customer weakness, and how the recall remediation affects orders.
- Whether inventory, cash conversion days, and working capital decline as component availability improves and expansions ramp.
- Debt and interest-cost trajectory, covenant headroom, and renewal or replacement of the $50 million facility maturing in February 2024.
- Whether improved gross margin is sustainable amid competitive pricing, cost inflation, and utilization changes.
- How open orders convert to sales, given the disclosed 15% year-over-year decline and customer cancellation or delay rights.